NCT06122077ClinicalTrials.gov

Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening

The PROACT LUNG Study: A Prospective, Observational,Clinical Validation Study of the Freenome Multiomics Blood Test for Lung Cancer Screening (FRNM-007)

RekrutiertNimmt laut Registereintrag derzeit Teilnehmende auf.

Diese Studie kontaktieren

Kurz gefasst

The PROACT LUNG study is a prospective multi-center observational study to validate a blood-based test for the early detection of lung cancer by collecting blood samples from high-risk participants who will undergo a routine, standard-of-care screening Low-Dose Computed Tomography (LDCT).

Beobachtend20.000 Teilnehmende gesucht36 Studienzentren1 Land

Kategorien

Onkologie56%Atemwege32%Infektionskrankheiten12%

In 1 Register registriert

ClinicalTrials.govNCT06122077Diesen Eintrag bei ClinicalTrials.gov öffnenSynchronisiert vor 2 Monaten

Eine Studie kann in mehreren Registern registriert sein. Wir zeigen sie einmal und verlinken jeden Eintrag, den wir haben.

Die Studieninformationen werden so angezeigt, wie sie vom Register veröffentlicht wurden, in ihrer Originalsprache.

Interesse an dieser Studie?

Anmelden oder ein Konto erstellen um Ihr Interesse zu bekunden und diese Studie zu verfolgen.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

Present: Registered before enrolment beganFirst posted 2023-11-08; recorded start 2023-11-28
Present: Has a defined primary outcomeA primary outcome measure is listed in the record
Present: The primary outcome states a time frameThe primary outcome measure records a time frame
Not stated: Whether participants are randomly assigned is not stated in the registry recordNo allocation method is recorded
Not stated: Whether there is a comparison group is not stated in the registry recordThe record does not describe the study arms
Not stated: Whether the study is blinded is not stated in the registry recordNo masking information is recorded
Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
Present: Sponsor has 1 other study in this databaseCounted from the lead sponsor named in the record (Freenome Holdings Inc.)
Not stated: No posted results from this sponsor are in this database yetBased on the sponsor’s studies in this database

The record lists 1 condition.
Lead sponsor type recorded as: industry.

These are facts from the public registry record, not a judgement about the study. Discuss any trial with your own doctor before taking part.

What these facts mean, and what to ask · ruleset v1

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourEXPLORATORY

An exploratory-stage design for a study of this type, judged from its ClinicalTrials.gov record.

How this score is built

Randomised allocation0/20
Allocation not stated in the record
Blinding0/20
Masking not stated in the record
Control arm0/15
No comparator arm stated in the record
Primary-outcome specificity10/10
Named primary outcome with a defined time frame
Endpoint type3/10
Surrogate or intermediate endpoint (conservative default)
Multi-centre8/8
Multi-centre: 36 sites
Data monitoring committee7/7
A data monitoring committee is in place
Prospective registration5/5
Registered before the study start date
Protocol / SAP posted0/5
No protocol or SAP posted to the registry

ScaleMEGA

A very large study: 20,000 participants (target), run at 36 sites.

How this score is built

Enrolment40/40
20,000 participants (target)
Site count18/25
36 sites
Country count0/15
Single country
Planned duration9/10
Planned over about 43 months
Sponsor scale1/10
Freenome Holdings Inc. has led 2 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built

Investigator standing0/100
No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Zusammenfassung

This is a prospective, multi-center, observational study to evaluate the performance of the Freenome Multiomics Blood Test in screening eligible participants for lung cancer. Enrollment will be open to all eligible participants for screening chest CT scan as part of the Standard of Care (SOC) for lung cancer. Subjects who meet the eligibility criteria for this study and provide informed consent will be enrolled and blood sample collection must be completed within 30 days of signing the informed consent. Optimally, the screening chest CT will be completed on the same day of the study blood collection, however up to 45 days will be allowed after study blood collection to obtain a screening chest CT. The study will also collect demographic data and relevant clinical data, such as medical history, lifestyle, occupational and environmental exposure(s), family history, and clinical laboratory data. All reports and clinical notes regarding the diagnostic tests and procedures related to lung cancer diagnosis or lung lesion assessment, such as histopathology and bronchoscopy reports, and diagnostic/follow-up images and imaging reports will be collected as part of follow up to the screening chest CT scan. All enrolled subjects will be followed prospectively from the date of the baseline screening chest CT until a minimum of 24 months, or until a premature study endpoint inclusive of withdrawal of consent or death.

Erkrankungen

Lung Cancer Diagnosis

Eignung

Eignung
Geschlecht	Alle
Alter	50 Years – Kein Höchstalter
Gesunde Freiwillige	Nein
Stichprobenverfahren	PROBABILITY_SAMPLE

Studienpopulation

The study aims to enroll a representative sample of the population across the United States including adults aged 50 years and older who have at least a 20-pack-year smoking history and who have met the eligibility criteria defined in this protocol.

Eignung im Wortlaut des Registers

Inclusion Criteria: 1. Age 50 years or older within 30 days of enrollment 2. Current or former smokers with a cumulative smoking history of ≥ 20 pack-year 3. Able to comprehend and willing to sign and date the informed consent and HIPAA authorization documents Exclusion Criteria: 1. Any active therapy for cancer, including but not limited to surgery, chemotherapy, biologic therapy, immunotherapy, and/or radiation therapy at the time of enrollment 2. History of any malignancy within prior 5 years of enrollment (except for non- melanoma skin cancer) 3. History of organ, tissue, and bone marrow transplantation 4. Screened for lung cancer or having chest CT scan 12 months before enrollment 5. Having signs and symptoms of lung cancer such as hemoptysis, superior vena cava syndrome, Cushing syndrome, and Pancoast syndrome 6. Received a blood transfusion in the 30 days preceding enrollment 7. Known to be pregnant 8. Participated or currently participating in another Freenome-sponsored clinical study 9. Participated or currently participating in a clinical research study in which an experimental medication has been administered during the 60 days preceding enrollment 10. Any condition that in the opinion of the Investigator should not be enrolled in the study

Eignung in einfachen Aussagen

Die Kriterien dieses Eintrags wurden noch nicht in einzelne Aussagen aufgeschlüsselt. Der Registertext oben ist vollständig und ist die maßgebliche Fassung.

Studiendesign

Studiendesign
Studientyp	Beobachtend
Phase	Im Registereintrag nicht angegeben
Zuteilung	Im Registereintrag nicht angegeben
Interventionsmodell	Im Registereintrag nicht angegeben
Primäres Ziel	Im Registereintrag nicht angegeben
Verblindung	Im Registereintrag nicht angegeben
Teilnahme	20.000 Teilnehmende gesucht

Sponsor und Mitwirkende

Freenome Holdings Inc. Sponsor

Interventionen

Diagnostischer Test blood draw
Subjects who provide informed consent and meet the eligibility criteria will have 50 ml of blood collected and sent to Freenome or Freenome's designee for processing, testing, and storage, and will then complete a standard-of-care screening LDCT.

Endpunkte

Primärer Endpunkt
Sensitivity and specificity in detecting lung cancer
Clinical performance of the Freenome Blood Test, including sensitivity and specificity, in detecting lung cancer in subjects with positive and negative lung cancer outcomes during a 12-month follow-up period
Zeitrahmen 12-Months
Sekundärer Endpunkt
Sensitivity and specificity in detecting lung cancer
Clinical performance of the Freenome Blood Test, including sensitivity and specificity, in detecting lung cancer in subjects with positive and negative lung cancer outcomes during a 24-month follow-up period
Zeitrahmen 24-Months

Daten

Daten
Startdatum	28. November 2023 (tatsächlich)
Primärer Abschluss	15. Juni 2026 (geschätzt)
Abschluss	15. Juni 2027 (geschätzt)
Erstveröffentlichung	8. November 2023 (tatsächlich)
Zuletzt aktualisiert	5. August 2025
Ergebnisse veröffentlicht	Im Registereintrag nicht angegeben
Status zuletzt bestätigt	August 2025

Tatsächlich bedeutet, dass das Ereignis eingetreten ist. Geschätzt bedeutet, dass der Sponsor es erwartet. Die beiden bedeuten Unterschiedliches.

Standorte

36 Studienzentren rekrutieren

United States

United States
Einrichtung	Stadt	Bundesland oder Region	Status
Ascension St. Agnes Hospital	Baltimore	Maryland	Rekrutiert
Our Lady of Lourdes Hospital	Binghamton	New York	Rekrutiert
Medical University of South Carolina (MUSC)	Charleston	South Carolina	Rekrutiert
University of Chicago	Chicago	Illinois	Rekrutiert
Hillcrest Medical Research	DeLand	Florida	Rekrutiert
Walgreens	Deerfield	Illinois	Rekrutiert
Universal Axon Clinical Research	Doral	Florida	Rekrutiert
Clinical Research Associates of Central PA	DuBois	Pennsylvania	Rekrutiert
McLeod Health	Florence	South Carolina	Rekrutiert
SpeciCare, Inc	Gainesville	Georgia	Rekrutiert
Altru Health System	Grand Forks	North Dakota	Rekrutiert
Memorial Hospital at Gulfport	Gulfport	Mississippi	Rekrutiert
Horizon Clinical Research Group	Houston	Texas	Rekrutiert
Cape Cod Hospital	Hyannis	Massachusetts	Rekrutiert
The Jackson Clinic, PA	Jackson	Tennessee	Rekrutiert
I.H.S Health, LLC	Kissimmee	Florida	Rekrutiert
US Digestive Health at Lancaster	Lancaster	Pennsylvania	Rekrutiert
Aton Health	Leawood	Kansas	Rekrutiert
Science 37	Los Angeles	California	Rekrutiert
Ascension Columbia St. Mary's Wisconsin	Milwaukee	Wisconsin	Rekrutiert
Inspira Medical Center	Mullica Hill	New Jersey	Rekrutiert
Hightower Clinical	Oklahoma City	Oklahoma	Rekrutiert
Temple University	Philadelphia	Pennsylvania	Rekrutiert
Circle Clinical Research	Pierre	South Dakota	Rekrutiert
United Medical Research	Port Orange	Florida	Rekrutiert
Oregon Health & Science University	Portland	Oregon	Rekrutiert
Wakemed	Raleigh	North Carolina	Rekrutiert
Renown Regional Medical Center	Reno	Nevada	Rekrutiert
Guthrie Medical Group	Sayre	Pennsylvania	Rekrutiert
Springfield Clinic, LLP	Springfield	Illinois	Rekrutiert
Stamford Hospital	Stamford	Connecticut	Rekrutiert
Charter Research	The Villages	Florida	Rekrutiert
CHRISTUS Trinity Mother Frances Health System	Tyler	Texas	Rekrutiert
Ascension Via Christi Wichita	Wichita	Kansas	Rekrutiert
Charter Research	Winter Park	Florida	Rekrutiert
US Digestive Health at Wyomissing	Wyomissing	Pennsylvania	Rekrutiert

Studiendokumente

In diesem Registereintrag sind keine Dokumente verlinkt.

Änderungen im Zeitverlauf

Seit wir diesen Eintrag erstmals eingelesen haben, wurden keine Änderungen erfasst.

Eine Änderung wird jedes Mal erfasst, wenn der Sponsor den Registereintrag aktualisiert. Status, Daten, Teilnahme und Studienzentren erscheinen hier, sobald sie sich ändern.

https://xmedica.io/trials/ctgov/NCT06122077